Effect of Lithium Carbonate in HIV‐infected Patients with Immune Dysfunction
作者:
David,
Parenti Gary,
Simon Rochelle,
Scheib William,
Meyer Marcelo,
Sztein Helene,
Paxton Richard,
DiGioia Richard,
期刊:
Journal of Acquired Immune Deficiency Syndromes
(OVID Available online 1988)
卷期:
Volume 1,
issue 2
页码: 119-124
ISSN:0894-9255
年代: 1988
出版商: OVID
关键词: Lithium carbonate;Immune dysfunction;HIV infection.
数据来源: OVID
摘要:
SummaryTen homosexual men received oral lithium carbonate at doses that maintained their serum lithium concentrations between 0.5 and 1.5 mEq/L. Prior to treatment all patients had HIV isolated from PHA-activated peripheral blood lymphocytes (PBLs) using a quantitative antigen-capture enzyme-linked immunosorbent assay (ELISA) assay for detection, and had an absolute number of CD4 (helper) lymphocytes of <300/mm3. Eight of 10 patients developed symptoms of drug toxicity requiring discontinuation of the drug in 7 patients. Two patients completed only 4–5 weeks of lithium therapy, and 5 patients received 7–8 weeks. All patients remained culture positive for HIV during the trial, and viral titers as measured by the antigen capture assay were unchanged or increased. There were no significant changes in the absolute number of CD4 lymphocytes, CD4/CD8 ratio, or phytohemagglutinin (PHA) or tetanus toxoid induced proliferative responses. There was a significant decrease in mixed lymphocyte reaction (MLR). Lithium carbonate demonstrated no immunorestora-tive or antiviral activity when given in therapeutic doses. Drug toxicity limited therapy in the majority of patients.
点击下载:
PDF
(392KB)
返 回